The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Open accessAbstract
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Self-citationBlinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Self-citationT-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Huang, A. C., Postow, M. A., Orlowski, R. J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J. R., Wenz, B., et al. (2017) · Nature · doi:10.1038/nature22079 · Cited by 1,664
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,444
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,293
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 914
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,004
Newly developed 3D in vitro models to study tumor–immune interaction
Mu, P., Zhou, S., Lv, T., Xia, F., Shen, L., Wan, J., Wang, Y., Zhang, H., Cai, S., Peng, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02653-w · Cited by 87
Self-citationElsallab, M., Levine, B. L., Wayne, A. S., & Abou-El-Enein, M. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30729-6 · Cited by 81
Chang, Y., Zhao, X., & Huang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03041 · Cited by 81
Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy
Nawaz, W., Xu, S., Li, Y., Huang, B., Wu, X., & Wu, Z. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.04.015 · Cited by 82
Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas
Salvaris, R., Ong, J., & Gregory, G. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050355 · Cited by 83
Kampouri, E., Walti, C. S., Gauthier, J., & Hill, J. A. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2063833 · Cited by 84
The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma
Simon, B., Wiesinger, M., März, J., Wistuba‐Hamprecht, K., Weide, B., Schuler‐Thurner, B., Schuler, G., Dörrie, J., & Uslu, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082365 · Cited by 80
Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds
Zhang, D. K. Y., Cheung, A. S., & Mooney, D. J. (2020) · Nature Protocols · doi:10.1038/s41596-019-0249-0 · Cited by 82
Wudhikarn, K., Flynn, J. R., Rivière, I., Gönen, M., Wang, X., Sénéchal, B., Curran, K. J., Roshal, M., Maslak, P. G., Geyer, M. B., et al. (2021) · Blood · doi:10.1182/blood.2020009515 · Cited by 80
Self-citationCD19 CAR antigen engagement mechanisms and affinity tuning
He, C., Mansilla‐Soto, J., Khanra, N., Hamieh, M., Bustos, V., Paquette, A. J., Angus, A. G., Shore, D. M., Rice, W. J., Khelashvili, G., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf1426 · Cited by 83
Self-citationEngineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 80
Leung, W., Gay, J. W., Martin, U., Garrett, T. E., Horton, H. M., Certo, M. T., Blazar, B. R., Morgan, R. A., Gregory, P. D., Jarjour, J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124430 · Cited by 81
Byrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
Role of Telomeres and Telomeric Proteins in Human Malignancies and Their Therapeutic Potential
Fernandes, S. G., Dsouza, R., Pandya, G., Kirtonia, A., Tergaonkar, V., Lee, S. Y., Garg, M., & Khattar, E. (2020) · Cancers · doi:10.3390/cancers12071901 · Cited by 80
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Uribe‐Herranz, M., Klein-González, N., Rodríguez‐Lobato, L. G., Juan, M., & de Larrea, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031026 · Cited by 84
Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E. L., Mavroukakis, S. A., Pacenta, H. L., Rossoff, J. E., Stefanski, H. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005564 · Cited by 79
Self-citationAl‐Okaily, M., Almajali, D., Al-Okaily, A., & Majali, T. (2023) · Journal of financial reporting & accounting · doi:10.1108/jfra-05-2023-0277 · Cited by 79
Fratricide-resistant CD7-CAR T cells in T-ALL
Oh, B. L. Z., Shimasaki, N., Coustan‐Smith, E., Chan, E., Poon, L. M., Lee, S. H. R., Yeap, F., Tan, L. K., Chai, L. Y. A., Bert, N. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03228-8 · Cited by 79
CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Long, K. B., Young, R. M., Boesteanu, A. C., Suhoski, M. M., Melenhorst, J. J., Lacey, S. F., Degaramo, D. A., Levine, B. L., & Fraietta, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02740 · Cited by 80
A novel era of cancer/testis antigen in cancer immunotherapy
Meng, X., Sun, X., Liu, Z., & He, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107889 · Cited by 84
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Shimabukuro‐Vornhagen, A., Böll, B., Schellongowski, P., Valade, S., Metaxa, V., Azoulay, É., & von Bergwelt‐Baildon, M. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21702 · Cited by 81
Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 79
Lei, W., Liu, H., Deng, W., Chen, W., Liang, Y., Gao, W., Yuan, X., Guo, S., Li, P., Wang, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00940-3 · Cited by 78
Jabbour, E. J., Gökbuget, N., Kantarjian, H. M., Thomas, X., Larson, R. A., Yoon, S., Ghobadi, A., Topp, M. S., Tran, Q., Franklin, J. L., et al. (2019) · Cancer · doi:10.1002/cncr.32335 · Cited by 78
An, F., Wang, H., Liu, Z., Wu, F., Zhang, J., Tao, Q., Li, Y., Shen, Y., Ruan, Y., Zhang, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19774-x · Cited by 79
Self-citationQin, H., Yang, L., Chukinas, J. A., Shah, N. N., Tarun, S., Pouzolles, M., Chien, C. D., Niswander, L. M., Welch, A. R., Taylor, N. N., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003149 · Cited by 78
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Halton, E. F., Lamanna, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.018 · Cited by 76
Self-citationImber, B. S., Sadelain, M., DeSelm, C. J., Batlevi, C. L., Brentjens, R. J., Dahi, P. B., Giralt, S., Park, J. H., Sauter, C. S., Scordo, M., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16541 · Cited by 76
Self-citationTherapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
Lymphocytes in Cellular Therapy: Functional Regulation of CAR T Cells
Dwivedi, A., Karulkar, A., Ghosh, S., Rafiq, A., & Purwar, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03180 · Cited by 78
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
Miao, L., Zhang, J., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840956 · Cited by 76
Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Luo, Y., Yang, J., Yu, J., Liu, X., Yu, C., Hu, J., Shi, H., & Ma, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00048 · Cited by 74
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 76
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
Kozani, P. S., Kozani, P. S., Najafabadi, M. A., Yousefi, F., Mirarefin, S. M. J., & Rahbarizadeh, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.795164 · Cited by 75
Zhang, N., Liu, X., Qin, J., Sun, Y., Xiong, H., Lin, B., Liu, K., Tan, B., Zhang, C., Huang, C., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.015 · Cited by 75
Li, X., Gong, N., Tian, F., Zhang, S., Zhang, Y., Wang, Y., Qing, G., Wang, Y., Li, F., Xu, Y., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01084-4 · Cited by 77
Self-citationIn situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity
Gong, N., Han, X., Xue, L., El-Mayta, R. D., Metzloff, A. E., Billingsley, M. M., Hamilton, A. G., & Mitchell, M. J. (2023) · Nature Materials · doi:10.1038/s41563-023-01646-6 · Cited by 76
Abbott, R. C., Cross, R. S., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020515 · Cited by 76
Rovatti, P. E., Gambacorta, V., Lorentino, F., Ciceri, F., & Vago, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00147 · Cited by 74
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Shalabi, H., Gust, J., Taraseviciute, A., Wolters, P. L., Leahy, A. B., Sandi, C., Laetsch, T. W., Wiener, L. S., Gardner, R. A., Nussenblatt, V. R., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00456-y · Cited by 74
Self-citationWei, G., Zhang, Y., Zhao, H., Wang, Y., Liu, Y., Liang, B., Wang, X., Xu, H., Cui, J., Wu, W., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0675 · Cited by 73
Self-citationCharacterization of extramedullary disease in B-ALL and response to CAR T-cell therapy
Holland, E. M., Yates, B., Ling, A. L., Yuan, C. M., Wang, H., Stetler‐Stevenson, M., LaLoggia, M., Molina, J. C., Lichtenstein, D. A., Lee, D. W., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006035 · Cited by 73
Ruffo, E., Butchy, A., Tivon, Y., So, V., Kvorjak, M., Parikh, A. B., Adams, E. L., Miškov-Živanov, N., Finn, O. J., Deiters, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37863-5 · Cited by 76
Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape
Zhai, Y., Du, Y., Li, G., Yu, M., Hu, H., Pan, C., Wang, D., Shi, Z., Yan, X., Li, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01708-w · Cited by 74
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Zhang, B., Yang, M., Zhang, W., Liu, N., Wang, D., Jing, L., Xu, N., Yang, N., & Ren, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06438-7 · Cited by 73
The Biology of B-Progenitor Acute Lymphoblastic LeukemiaPreprint
Roberts, K. G., & Mullighan, C. G. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034835 · Cited by 76
SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors
López-Cobo, S., Fuentealba, J. R., Gueguen, P., Bonté, P.-E., Tsalkitzi, K., Chacón, I., Glauzy, S., Bohineust, A., Biquand, A., Silva, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1350 · Cited by 72
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
Zolov, S. N., Rietberg, S. P., & Bonifant, C. L. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.07.005 · Cited by 73
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J., & Brentjens, R. J. (2020) · Leukemia · doi:10.1038/s41375-020-0874-1 · Cited by 73
Self-citationPrevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress
Matuszkiewicz‐Rowińska, J., & Małyszko, J. (2020) · Kidney & Blood Pressure Research · doi:10.1159/000509934 · Cited by 74
The CAR T‐Cell Mechanoimmunology at a Glance
Li, R., Ma, C., Cai, H., & Chen, W. (2020) · Advanced Science · doi:10.1002/advs.202002628 · Cited by 75
Driouk, L., Gicobi, J. K., Kamihara, Y., Rutherford, K. D., Dranoff, G., Ritz, J., & Baumeister, S. H. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580328 · Cited by 73
Emerging Immunotherapy for Acute Myeloid Leukemia
Tabata, R., Chi, S., Yuda, J., & Minami, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041944 · Cited by 74
Zhao, Y., Liu, D., Sun, R., Zhang, J., Zhou, J., Wei, Z., Xiong, M., Cao, X., Lü, Y., Yang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.605766 · Cited by 73
Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors
Akbari, P., Katsarou, A., Daghighian, R., van Mil, L. W. H. G., Huijbers, E. J. M., Griffioen, A. W., & B, J. R. V. B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188701 · Cited by 72
Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities
Vasic, D., Lee, J. B., Leung, Y. K., Khatri, I. A., Na, Y., Abate‐Daga, D., & Li, Z. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl3642 · Cited by 73
CD58 loss in tumor cells confers functional impairment of CAR T cells
Yan, X., Chen, D., Ma, X., Wang, Y., Guo, Y., Wei, J., Tong, C., Zhu, Q., Lu, Y., Yu, Y., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007891 · Cited by 77
Self-citationEfficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73
Jung, I.-Y., Noguera-Ortega, E., Bartoszek, R. L., Collins, S. M., Williams, E. F., Suhoski, M. M., Jadlowsky, J. K., Plesa, G., Siegel, D. L., Chew, A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101053 · Cited by 74
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 75
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 76
Wiebking, V., Lee, C. M., Mostrel, N., Lahiri, P., Bak, R. O., Bao, G., Roncarolo, M. G., Bertaina, A., & Porteus, M. H. (2020) · Haematologica · doi:10.3324/haematol.2019.233882 · Cited by 73
Cellular therapy: Immune‐related complications
Oved, J. H., Barrett, D. M., & Teachey, D. T. (2019) · Immunological Reviews · doi:10.1111/imr.12768 · Cited by 72
In Situ Programming of CAR T Cells
Parayath, N. N., & Stephan, M. T. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070620-033348 · Cited by 73
Deconvolution of clinical variance in CAR-T cell pharmacology and response
Kirouac, D. C., Zmurchok, C., Deyati, A., Sicherman, J., Bond, C., & Zandstra, P. W. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01687-x · Cited by 73
Gagelmann, N., Ayuk, F. A., Atanackovic, D., & Kröger, N. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13380 · Cited by 73
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Neureiter, D., Stintzing, S., Kiesslich, T., & Ocker, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i25.3136 · Cited by 70
DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., Jabbour, E. J., Merchant, A. A., Wang, T., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00345-8 · Cited by 71
Ouyang, W., Jin, S., Xu, N., Liu, W.-Y., Zhao, H. Q., Zhang, L., Kang, L., Tao, Y., Liu, Y., Wang, Y., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008429 · Cited by 71
Self-citationStein, A. S., Kantarjian, H. M., Gökbuget, N., Bargou, R. C., Litzow, M. R., Rambaldi, A., Ribera, J., Zhang, A., Zimmerman, Z. F., Zugmaier, G., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.010 · Cited by 70
Lee, J. B., Kang, H., Fang, L., D’Souza, C. A., Adeyi, O. A., & Li, Z. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2291 · Cited by 71
Britten, O., Ragusa, D., Tosi, S., & Kamel, Y. M. (2019) · Cells · doi:10.3390/cells8111341 · Cited by 74
Heng, G., Jia, J., Li, S., Fu, G., Wang, M., Qin, D., Li, Y., Li, P., Tian, X., Zhang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1339 · Cited by 70
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia
Pastorczak, A. K., Domka, K., Fidyt, K., Poprzeczko, M., & Firczuk, M. (2021) · Cancers · doi:10.3390/cancers13071536 · Cited by 71
Li, Y., Ming, Y., Fu, R., Li, C., Wu, Y., Jiang, T., Li, Z., Ni, R., Li, L., Su, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.950923 · Cited by 75
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan, A. N., Asija, S., Pendhari, J., & Purwar, R. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14076 · Cited by 72
In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles
Zhao, G., Zhang, Y., Xu, C., & Wang, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.11.055 · Cited by 70
Gutiérrez, C., McEvoy, C. A., Mead, E., Stephens, R. S., Munshi, L., Detsky, M. E., Pastores, S. M., & Nates, J. L. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003258 · Cited by 70
Self-citationBrück, O. E., Dufva, O., Hohtari, H. R., Blom, S., Turkki, R., Ilander, M. M., Kovanen, P. E., Pallaud, C., Ramos, P. M., Lähteenmäki, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000792 · Cited by 71
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71
Song, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 68
Toward Better Understanding and Management of CAR-T Cell–Associated Toxicity
Schmidts, A., Wehrli, M., & Maus, M. V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-061119-015600 · Cited by 69
CXCR5 guides migration and tumor eradication of anti-EGFR chimeric antigen receptor T cells
Li, G., Guo, J., Zheng, Y., Ding, W. Y., Han, Z., Qin, L., Mo, W., & Luo, M. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.07.003 · Cited by 68
Summers, C. N., Wu, Q. V., Annesley, C., Bleakley, M., Dahlberg, A. E., Narayanaswamy, P., Huang, W., Voutsinas, J. M., Brand, A., Leisenring, W. M., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.10.003 · Cited by 68
Self-citationTandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer
Liang, Z. C., Dong, J., Yang, N., Li, S.-D., Yang, Z., Huang, R., Li, F., Wang, W., Ren, J.-K., Lei, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.63181 · Cited by 68
Self-citationBacterial l ‐asparaginases for cancer therapy: Current knowledge and future perspectives
Ghasemian, A., AL-Marzoqi, A. H., Al-Abodi, H. R., Alghanimi, Y. K., Kadhum, S. A., Mostafavi, S. K. S., & Fattahi, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28563 · Cited by 68
NK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 68
Guha, A., Addison, D., Jain, P., Gutierrez, J. M., Ghosh, A. K., Roddie, C., Lima, M. J. G. D., Al-Kindi, S. G., & Oliveira, G. H. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.036 · Cited by 69
CAR T cells: Building on the CD19 paradigm
Levin, A. G., Rivière, I., Eshhar, Z., & Sadelain, M. (2021) · European Journal of Immunology · doi:10.1002/eji.202049064 · Cited by 68
Self-citationLei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K. H., & Qian, W. (2021) · Cancers · doi:10.3390/cancers13153912 · Cited by 70
Miller, K. C., Johnson, P. C., Abramson, J. S., Soumerai, J. D., Yee, A. J., Branagan, A. R., O’Donnell, E., Saucier, A., Jacobson, C. A., Frigault, M. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00741-2 · Cited by 70
Antigen loss following CAR‐T cell therapy: Mechanisms, implications, and potential solutions
Mishra, A., Maiti, R., Mohan, P., & Gupta, P. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14101 · Cited by 70
Honing CAR T cells to tackle acute myeloid leukemia
Haubner, S., Subklewe, M., & Sadelain, M. (2024) · Blood · doi:10.1182/blood.2024024063 · Cited by 67
Self-citationCRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy
Salas-McKee, J., Kong, W., Gladney, W. L., Jadlowsky, J. K., Plesa, G., Suhoski, M. M., & Fraietta, J. A. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1571893 · Cited by 68
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 69
Harnessing organs-on-a-chip to model tissue regeneration
Tavakol, D. N., Fleischer, S., & Vunjak‐Novakovic, G. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.05.008 · Cited by 68
Wu, J., Meng, F., Cao, Y., Zhang, Y., Zhu, X., Wang, N., Wang, J., Huang, L., Zhou, J., & Xiao, Y. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00523-2 · Cited by 67
Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy
Fisher, J. P. H., & Anderson, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01409 · Cited by 67
Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
Hohtari, H. R., Brück, O. E., Blom, S., Turkki, R., Sinisalo, M., Kovanen, P. E., Kallioniemi, O., Pellinen, T. S., Porkka, K., & Mustjoki, S. M. (2019) · Leukemia · doi:10.1038/s41375-018-0360-1 · Cited by 67
Smith, C., Lineburg, K. E., Martins, J. P., Ambalathingal, G. R., Neller, M. A., Morrison, B., Matthews, K. K., Rehan, S., Crooks, P., Panikkar, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138649 · Cited by 65
Metadata
- Authors
- Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From the Leukemia Service, Department of Medicine (J.H.P., C.S., P.M., R.J.B.), the Michael G. Harris Cell Therapy and Cell Engineering Facility (I.R., X.W., B. Sénéchal, Y.W.), the Center for Cell Engineering (J.H.P., I.R., X.W., R.J.B., M.S.), and the Departments of Epidemiology and Biostatistics (M.G.), Pediatrics (K.J.C.), Neurology (B. Santomasso), Anesthesiology and Critical Care Medicine (E.M.), and Pathology (M.R.), Memorial Sloan Kettering Cancer Center, and the Department of Medicine, Joan...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 449-459
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6637939
- OpenAlex
- W2787621143
- Cited by
- 2,688
- References
- 24
- Citations by year
- 2026: 164 · 2025: 235 · 2024: 306 · 2023: 351 · 2022: 365 · 2021: 403 · 2020: 412 · 2019: 290 · 2018: 156
- FWCI
- 118.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Comprehensive Cancer Network Foundation (Young Investigator Award)
- Emerald Foundation
- National Institute of Health (R01CA138738-05, P01CA059350, P01CA190174-01)
- Leukemia and Lymphoma Society (Career Development Award)
- American Society of Clinical Oncology (Career Development Award)
- Memorial Sloan Kettering Cancer Center Support Grant (P30CA008748)
- Juno Therapeutics
- Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center
- Stand Up To Cancer
- William Lawrence and Blanche Hughes Foundation
- Annual Terry Fox Run for Cancer Research
- Carson Family Charitable Trust
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 CAR T cells, B-cell acute lymphoblastic leukemia, relapsed leukemia, autologous T cell therapy, cytokine release syndrome, neurotoxicity, disease burden, bone marrow blasts, event-free survival, overall survival, long-term outcomes
- MeSH terms
- Adult, Aged, Follow-Up Studies, Humans, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Remission Induction, T-Lymphocytes, Survival Analysis, Cytokines, Precursor Cell Lymphoblastic Leukemia-Lymphoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
